The role of glycosaminoglycans in the management of chronic pelvic pain: a systematic review

Minerva Urol Nefrol. 2020 Jun;72(3):321-331. doi: 10.23736/S0393-2249.20.03672-3. Epub 2020 Mar 16.

Abstract

Introduction: Glycosaminoglycans (GAGs) are involved in the pathogenesis of several urologic chronic diseases. Thus, GAGs replenishment therapy is widely reported as a therapeutic tool for chronic pelvic pain (CPP) conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and prostate pain syndrome/chronic prostatitis. In this article we reviewed the current status of evidence on the clinic applications of glycosaminoglycans (GAGs) in the CPP.

Evidence acquisition: A literature search from inception was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement to identify clinical trials, randomized controlled trials, meta-analyses, and guidelines.

Evidence synthesis: A total of 29 papers were identified regarding the use of GAGs in CPP.

Conclusions: GAGs replenishment therapy results are encouraging in chronic forms of pelvic pain even though well-powered randomized clinical trials are needed to better comprehend the exact role of this treatment.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Chronic Pain / drug therapy*
  • Glycosaminoglycans / therapeutic use*
  • Humans
  • Pelvic Pain / drug therapy*
  • Randomized Controlled Trials as Topic

Substances

  • Glycosaminoglycans